Home > Update to the Lynparza® (olaparib) Adjuvant breast cancer (OlympiA) Patient Support Program – Free D
View in browser | FR






Dear Health Care Provider,

As part of a global strategic oncology collaboration between AstraZeneca and Merck to co-develop and co-commercialize Lynparza® (olaparib), AstraZeneca Canada and Merck Canada opened a Patient Support Program (PSP) on July 25, 2022 for the adjuvant treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (BRCAm), human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. This PSP provided patients with reimbursement navigation support and access to educational resources. On August 5, 2022, the PSP was expanded to include drug free of charge for patients who meet pre-specified eligibility criteria.

We are now writing to inform you that the planned closure of enrollment into the free drug component of the Lynparza adjuvant breast cancer PSP is September 8th, 2023. With the forthcoming closure of new enrollments, AstraZeneca Canada and Merck Canada are discontinuing the free drug component of the PSP for all NEW patients starting treatment beginning September 9th, 2023. Details regarding the refined PSP program are outlined below:
  • All eligible patients enrolled in the free drug component of the adjuvant breast cancer PSP and who have started treatment with Lynparza on or before September 8th, 2023, will continue to receive uninterrupted access to Lynparza for the duration of their treatment either through the PSP or at a future date through their provincial drug plan if they are eligible for transition.

  • All new adjuvant breast cancer patients prescribed Lynparza who are enrolled into the PSP and wish to start on treatment on or after September 9, 2023, will still have access to educational resources, reimbursement navigation support and, for eligible patients, co-payment support towards the cost of Lynparza (up to 20%). The free drug component of the adjuvant breast cancer PSP will no longer be open for enrollment.


We will continue to keep you up to date on the status of the PSP free drug program and advise when it is time to begin transitioning patients to provincial funding.

If you have any questions, please do not hesitate to contact the Patient Support Program directly at 1-877-280-6208 or enrollment@azoncologypsp.ca.

Regards,
AstraZeneca Oncology Patient Support Program

*Lynparza® is part of a global strategic oncology collaboration between Merck and AstraZeneca. AstraZeneca Canada Inc ("AstraZeneca") is managing the Lynparza® Patient Support Program ("Program") on behalf of both companies via its existing AstraZeneca Oncology Patient Support Program.

Lynparza® and the AstraZeneca logo are registered trademarks of AstraZeneca AB, used under license by AstraZeneca Canada Inc. MERCK® is a registered trademark of Merck Sharp & Dohme LLC. Used under license. © 2023 AstraZeneca and Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.